 
                                                                                             
                                                                                            Motilal Oswal is bullish on Global Health has recommended buy rating on the stock with a target price of Rs 1630 in its research report dated August 10, 2025.
 
                                                                                            The market may attempt a bounce back after six weeks of consistent losses, but sustainability will be the key to watch. Below are some short-term trading ideas to consider.
 
                                                                                            Chart formation signals a lack of conviction among bulls and a clear dominance of bears at higher levels, said Sudeep Shah of SBI Securities.
 
                                                                                            Stocks to Watch, 8 August: Stocks like Titan Company, Bharti Airtel, Biocon, Cummins India, BSE, Life Insurance Corporation, KRBL, Metropolis Healthcare, Kalpataru Projects International, Godrej Consumer Products, Kalyan Jewellers, and CE Info Systems will be in focus on August 8.
 
                                                                                            Medanta has strong capabilities to leverage its brand image. However, near-term growth looks limited
 
                                                                                            Emkay Global Financial recommended reduce rating on Global Health with a target price of Rs 1175 in its research report dated May 17, 2025.
 
                                                                                             
                                                                                             
                                                                                            The company's board, in its meeting held on Monday, has approved the purchase of 3 acres of land from Assam Electricity Grid Corporation Ltd for Rs 30 crore plus incidental expenses for registration and possession of the land, the healthcare provider said in a regulatory filing.
 
                                                                                            The market may see some consolidation before gaining further strength toward the 20-day EMA. Below are some trading ideas for the near term.
 
                                                                                            Jefferies prefers hospital players that have higher brownfield bed expansion plans lined up for the coming years. Max Healthcare remains its top sectoral pick.
 
                                                                                            "There are actions that the US government is taking… which we're concerned are having a serious impact on global health," said Tedros in a virtual press conference from Geneva.
 
                                                                                            Emkay Global Financial recommended reduce rating on Global Health with a target price of Rs 1050 in its research report dated February 05, 2025.
 
                                                                                            Overall, the sentiment remains in favour of bulls despite Wednesday's consolidation. Below are some trading ideas for the near term.
 
                                                                                             
                                                                                             
                                                                                             
                                                                                            In contrast, HSBC projects a 10 percent and 27 percent downside for Global Health and Narayana Hrudayalaya, initiating coverage with 'reduce' ratings for both stocks.
 
                                                                                            Motilal Oswal is bullish on Global Health recommended buy rating on the stock with a target price of Rs 1380 in its research report dated September 06, 2024.
 
                                                                                             
                                                                                             
                                                                                            Even though long-term growth prospects remain intact for Global Health, slow near-term margin expansion due to consistent capex, along with the pricey valuations of the stock has triggered a selloff in the counter.
